Riskpilot← Back to searchSign inGet full accessOxiris AB
ABActiveOrg 5566609540Själbodgatan 10General medical practice activities · NACE 8621Est. 20040 employees
Revenue 2025
SEK 400K
+11% vs 2024
EBITDA margin
54.4%
+6% vs 2024
Equity ratio
68.6%
Financial strength
Net profit 2025
SEK 9,2M
+234% vs 2024
| Revenue | SEK 400K | +11% |
| EBITDA | SEK 218K | +6% |
| Net profit | SEK 9,2M | +234% |
| Total assets | SEK 14,5M | -6% |
| Equity | SEK 9,9M | +165% |
| Employees | 0 | — |
Legal name
Oxiris AB
Org number
5566609540
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
22 april 2004
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolagets verksamhet ska vara att bedriva hälso- och sjukvård, handla med antikviteter, äga och förvalta fastigheter och värdepapper samt därmed förenlig verksamhet.
Address
Själbodgatan 10
Email
oxiristm@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 360 | 400 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 236 | 201 | 119 | 206 | 218 |
| Depreciation & amort. | −152 | −149 | −232 | −232 | −232 |
| EBIT | 84 | 52 | −113 | −26 | −14 |
| Net financials | −79 | 8 412 | 1 224 | 2 776 | 8 620 |
| Profit before tax | 5 | 8 464 | 1 141 | 2 749 | 9 186 |
| Tax | −1 | −0 | −0 | — | −0 |
| Net profit | 4 | 8 464 | 1 141 | 2 749 | 9 185 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 18 404 | 23 234 | 17 579 | 15 376 | 14 467 |
| Equity | 7 887 | 11 351 | 8 992 | 3 741 | 9 926 |
| Long-term debt | 5 180 | 5 000 | 4 670 | 4 490 | 4 310 |
| Short-term debt | 5 337 | 6 883 | 3 917 | 7 145 | 231 |
| Total debt | 10 517 | 11 883 | 8 587 | 11 635 | 4 541 |
EBITDA margin
54.4%
This company
15.8%
Market median
+244% vs market
20212025
Equity ratio
68.6%
This company
38.2%
Market median
+80% vs market
20212025
Return on equity
92.5%
This company
18.4%
Market median
+403% vs market
20212025
Net profit margin
2296.3%
This company
8.1%
Market median
+28249% vs market
20212025
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212025
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KH Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oxiris AB 
Frisk & Skönhet i Båstad ABBoard members of Oxiris AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Henrik Mathias Nilsson | Chief Auditor | 0 companies |
| Mats Tuve Mårten Mårtensson | Board of Directors | 0 companies |
| Antonio Abel Perez | Deputy Board Member | 0 companies |